News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
The company said its test is faster, more precise, and cheaper than the current gold standard Cepheid GeneXpert test.
The blood-based test is designed to detect changes in levels of microRNAs that are enriched in specific brain regions affected by Alzheimer's disease.
The company launched last month with initial financing of $35 million and licenses to CRISPR and synthetic biology technology from the Broad and Harvard.
The company has initial financing of $35 million, and has licensed its foundational SHERLOCK and INSPECTR technologies from the Broad and Harvard, respectively.
The technology behind Mammoth's platform bears a striking resemblance to the CRISPR-based SHERLOCK platform developed by researchers at the Broad Institute.